Review article · 2025 · Open access
GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations
Advanced Drug Delivery Reviews, 229, 115744 · Published 2 December 2025 · DOI 10.1016/j.addr.2025.115744
In brief
“GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations” is a 2025 review article by Alexandra Haase and 2 co-authors, published in Advanced Drug Delivery Reviews. OpenAlex counts 26 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Advanced Drug Delivery Reviews.
- Citations
- 26
- Most cited in
- 2026 (26)
- Field-weighted impact
- 1.69
- References
- 105
- Authors
- 3
Abstract
The development of induced pluripotent stem cells (iPSCs) has transformed the field of regenerative medicine. However, to use iPSCs for therapeutic applications, iPSC-based products must be produced under Good Manufacturing Practice (GMP) conditions. This process involves reprogramming somatic cells, characterizing and banking iPSC lines, introducing therapeutic transgenes if necessary, and scaling up cell expansion and differentiation for clinical use. This review provides an overview of the relevant regulatory authorities and relevant regulations in the US, Europe, and Japan. It also discusses the current challenges and opportunities in producing GMP-compliant iPSCs. These challenges include the need for defined culture media, as well as developing all the required GMP-compliant processes, such as reprogramming, establishing iPSC clones, and manufacturing processes that lead to the final advanced therapy medicinal product (ATMP). For autologous products in particular, this can be complicated by cell line-specific variation of proliferation velocity and differentiation biases. The review also discusses attempts to develop automated closed systems. It emphasizes the importance of ensuring the sterility, identity, (epi)genetic integrity, and functionality of the final cell products to guarantee the safety and the efficacy of iPSC-based therapies. However, the need for reproducibility, rigorous quality control and safety requirements has resulted in high regulatory hurdles and extremely high costs, which often prevent the initiation of clinical trials. Overcoming these challenges will enable iPSCs to play an integral role in future medicine and offer new treatment options for various diseases.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Haase, A., Ruhparwar, A., & Martin, U. (2025). GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations. Advanced Drug Delivery Reviews, 229, 115744. https://doi.org/10.1016/j.addr.2025.115744
MLA 9
Haase, Alexandra, et al. “GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations.” Advanced Drug Delivery Reviews, vol. 229, 2025, p. 115744. https://doi.org/10.1016/j.addr.2025.115744.
Chicago
Haase, Alexandra, Arjang Ruhparwar, and Ulrich Martin. 2025. “GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations.” Advanced Drug Delivery Reviews 229: 115744. https://doi.org/10.1016/j.addr.2025.115744.
Harvard
Haase, A., Ruhparwar, A. and Martin, U. (2025) ‘GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations’, Advanced Drug Delivery Reviews, 229, p. 115744. doi:10.1016/j.addr.2025.115744.
IEEE
A. Haase, A. Ruhparwar, and U. Martin, “GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations,” Advanced Drug Delivery Reviews, vol. 229, p. 115744, 2025, doi: 10.1016/j.addr.2025.115744.
BibTeX
@article{haase2025compliant,
title = {{GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations}},
author = {Haase, Alexandra and Ruhparwar, Arjang and Martin, Ulrich},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
volume = {229},
pages = {115744},
doi = {10.1016/j.addr.2025.115744},
url = {https://doi.org/10.1016/j.addr.2025.115744}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- induced pluripotent stem cells
- GMP manufacturing
- advanced therapy medicinal products
- cellular reprogramming
- defined culture medium
- regulatory requirements
- autologous cell therapy
- cell line variability
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Haase, A., Ruhparwar, A., & Martin, U. (2025). GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations. Advanced Drug Delivery Reviews, 229, 115744. https://doi.org/10.1016/j.addr.2025.115744
How many times has this paper been cited?
26 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Advanced Drug Delivery Reviews: sign in and open the full text from this page.
Who wrote this paper?
Alexandra Haase, Arjang Ruhparwar, Ulrich Martin.
What is the DOI of this paper?
10.1016/j.addr.2025.115744, permanently at https://doi.org/10.1016/j.addr.2025.115744. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.